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Abstract
Introduction: Leptin is a hormone secreted by adipocytes 
that plays an important role in regulating appetite and 
energy expenditure. Our aim was to evaluate serum 
leptin level in hemodialysis (HD) patients with or without 
chronic liver disease (CLD) and study the relationship 
between serum leptin level and bone mineral density in 
these groups of patients.
Methods: we recruited 20 healthy volunteers as controls 
(group I), 20 patients on regular HD with normal liver 
function (group II), 20 CLD patients with normal kidney 
function (group III) and 20 patients on regular HD 
with CLD (group IV). We measured serum calcium, 
phosphorus, parathyroid hormone (PTH), total alkaline 
phosphatase (ALP), serum leptin, 24-hours urinary 
hydroxyproline and bone mineral density (BMD) of the 
lumber spine and femoral neck by DEXA scan.
Results: Serum leptin level was significantly higher 
(P <0.001) in HD patients and CLD patients compared 
to controls. Its level was also significantly elevated in 
HD patients without liver disease (group II) compared 
to patients with CLD who had no renal failure (group 
III). Urinary hydroxyproline level was increased in both 
HD patients and CLD patients. We detected a positive 
correlation between serum leptin level and urinary 
hydroxyproline in all patient groups. There was a 
significant decrease in BMD in HD and CLD patients. 
BMD was significantly lower in HD patients without 
CLD compared to HD patients with CLD. There was 
a significant negative correlation between serum leptin 
level and BMD in CLD patients without renal disease but 
not in other groups (r = - 0.6, P = 0.01).
Conclusion: Serum leptin is elevated in HD patients 
with or without liver disease and in CLD patients. Serum 
leptin level is inversely correlated with BMD in CLD 
patients without renal disease. 
Keywords: Bone Mineral Density; Cirrhosis; Chronic 
Liver Disease; Hemodialysis; Leptin
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Introduction
Leptin is a cytokine protein encoded by the ob gene and 
secreted from adipose tissue [1]. Circulating levels have 
been shown to be positively related to fat mass in both 
lean and obese individuals [2]. Leptin first emerged as a 
component of a regulatory loop linking fat mass to food 
intake and energy expenditure [3]. Peripherally, leptin 
is thought to exert positive effects on bone formation, 
while it has negative central effects on bone formation 
via specific receptors located on the hypothalamic nuclei 
[4].
Despite a preliminary understanding of leptin-skeletal 
interactions, the exact roles of leptin in bone metabolism 
have not yet been clarified. In vitro, leptin has been 
shown to exert direct osteotrophic effects by promoting 
differentiation of bone marrow stromal cells into 
osteoblasts [5] and by inhibiting osteoclast generation 
[6]. These data have been confirmed in different animal 
models, with peripheral leptin administration having 
positive effects on bone by modulating formation and 
resorption processes [7]. However, studies in humans 
have not been able to confirm these actions [8].
Leptin levels are increased in patients with end-stage 
renal disease (ESRD) [9]. Patients treated by peritoneal 
dialysis (PD) seem to have higher leptin levels compared 
to patients treated by hemodialysis (HD). This could 
be the effect of a marked increase in body fat mass as a 
consequence of the continuous carbohydrate load [9]. It 
has been speculated that hyperleptinemia may contribute 
to uremic anorexia and malnutrition [10].
Liver cirrhosis is a debilitating chronic disease associated 
with severe complications and high mortality. Hepatic 
osteodystrophy with consequent osteoporosis and 
increased risk of bone fracture represent some of the 
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more recently investigated complications. Initial studies 
focused on osteoporosis in patients with primary biliary 
cirrhosis. Recently, however, it has been shown that 
liver cirrhosis is a risk factor for osteoporosis and bone 
fractures independent of its etiology [11].
Methods
This work was carried out in the departments of Internal 
Medicine, Medical Biochemistry and Diagnostic 
Radiology, Faculty of Medicine, Zagazig University in 
the period from June 2006 to January 2009. We recruited 
40 patients with ESRD, 20 patients suffering from chronic 
liver disease (CLD) and 20 apparently healthy subjects. 
Exclusion criteria were:
1. Age above 60 years.
2. Menopause for females.
3. Thyroid dysfunction.
4. Obesity, defined by body mass index (BMI) ≥30 
     kg/m2 [12].
5. Hepatic neoplasm or other malignancy.
6. Obstructive jaundice.
7. Diabetes mellitus.
8. Drugs that affect mineral metabolism (corticosteroids, 
   cytotoxic drugs, estrogen or testosterone) in the past 
     six months.
Subjects were classified into four groups as follows:
Group I: Included 20 apparently healthy subjects (12 
males and 8 females) as a control group. Their age ranged 
from 22 to 47 years, with a mean ± SD of 47.4 ± 6.2 years. 
All were clinically normal and had normal hematological 
and biochemical profiles.
Group II: Included 20 ESRD patients (13 males and 7 
females) on regular hemodialysis with no liver disease. 
Their minimum duration on dialysis was one year. Their 
age ranged from 22 to 48 years, with a mean ± SD of 39.3 
± 6.3 years.
Group III: Included 20 CLD patients (9 males and 11 
females) without kidney disease. Their age ranged from 
28 to 49 years, with a mean ± SD of 38 ± 6 years. Nine 
patients had HCV infection, seven had HBV infection 
and four had both schistosomiasis and HCV infection. 
Shistomsomiasis was diagnosed by stool analysis or 
rectal snip for schistosoma ova. Group III patients 
were divided into 3 subgroups according to Child-Pugh 
classification: Child A (9 cases), Child B (5 cases) and 
Child C (6 cases).
Group IV: Included 20 ESRD patients (10 males and 10 
females) on regular HD for more than one year who also 
suffered from CLD. Their age ranged from 22 to 44 years, 
with mean ± SD of 36.4 ± 5.2 years. Eight patients had 
HCV infection, six had HBV infection, three had chronic 
schistosomiasis and three  had both chronic schistosomiasis 
and HCV infection. They were divided into 3 subgroups 
according to Child-Pugh classifications: Child A (8 cases), 
Child B (7 cases) and Child C (5 cases).
All patients of group II and III received 12 hours of 
HD weekly divided into 3 sessions by Fresenius 4008B 
machine, using “hemophane” membranes with surface 
area adjusted to every patient. Group II patients were 
dialyzed using acetate dialysis solutions (Na = 135-145, 
K = 0-4, Ca = 2.5-3.5, Mg = 0.5-1, chloride = 100-119, 
acetate = 35-38 and dextrose = 11 mEq/l). Group 
IV patients were dialyzed using bicarbonate dialysis 
solutions (Na = 135-145, K = 0-4, Ca = 2.5-3.5, Mg = 
0.5-l, chloride = 100-124, acetate = 2-4, dextrose = 11, 
and bicarbonate = 30-38 mEq/l). All patients of group II 
and IV were prescribed calcium carbonate 1500 mg/day 
and one-alpha-calcidol 0.25 mcg/day. 
All patients were interviewed for clinical  history and 
examination. General investigations included:  complete 
blood count, blood sugar, urine and stool analysis, total 
and direct bilirubin levels, liver enzymes, serum total 
proteins, serum albumin level, albumin/globulin ratio, 
prothrombin time, serum alkaline phosphatase , blood 
urea level and serum creatinine level. All tests were 
done using Hitachi 902 automatic analyzer. Abdominal 
ultrasound was done for all subjects. Viral hepatitis 
markers were detected by 3rd generation ELISA and 
confirmed by PCR. Specific investigations were done for 
all subjects, including:
1. Serum calcium level by colorimetric method; using 
     automatic photometer (Behring- ELISA).
2. Serum phosphorus level by colorimetric method; using 
    automatic photometer (Behring- ELISA).
3.  Assay of human intact parathyroid hormone. 
4. Estimation of serum leptin (BIOSOURCE LEPTIN 
     EASIA) 
5.  Determination of urinary hydroxyproline.      
6. Bone density measurement by DEXA scan (Norland 
   Radiation) on lumbar spine (LS) and femoral neck 
     (FN).
10ml of venous blood was collected from each patient 
before dialysis in groups II, IV and in the early morning 
(9AM) in groups I and III. The blood was allowed to clot 
and centrifugation and separation of serum were performed 
within 2 hours. The specimen was then divided into two 
tubes. One tube was used for routine investigations 
that were performed immediately. The other tube was 
labelled and stored at -20ºc until completion of the study 
and transported frozen on ice to relevant laboratories for 
calcium, phosphorus and leptin determination.
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The following statistical methods were used for analysis 
and summarization of results: arithmetic mean, standard 
deviation (SD), analysis of variance (ANOVA or F- 
test), least significance difference (LSD) and correlation 
coefficient (r) [13].
Results
The laboratory data of the studied groups are shown (Table 
1). There were highly significant differences between 
groups in total and corrected calcium, parathyroid hormone, 
serum leptin and 24-hour urinary hydroxyproline levels. 
Serum leptin and urinary hydroxyproline were higher in 
HD patients compared to the other groups. Table-2 shows 
that BMD at the level of lumbar spine and femoral neck 
was significantly decreased in all groups in comparison 
to controls. Difference was particularly evident between 
the group of ESRD without liver disease and the two 
other groups. 
Figure-1 shows lack of significant correlation between 
leptin level and BMD at the level of lumbar spine in 
group II (r = - 0.2, P = 0.3). Figure-2 shows the inverse 
correlation between leptin level and BMD at the level of 
lumbar spine in group III (r = - 0.6, P ˂0.01). Figure-3 
shows lack of significant correlation between leptin 
level and BMD at the level of lumbar spine in group IV 
(r = 0.2, P = 0.4).
Discussion
Leptin is a hormone secreted by adipocytes that plays 
an important role in regulating appetite and energy 
expenditure. It is also involved in the function of other 
systems, including the neuroendocrine, hematopoietic 
and immune systems [14]. Human studies have yielded 
conflicting data concerning the relationship between bone 
mineral density (BMD) and leptin. Some studies have 
reported a weak positive correlation [15] or a negative 
correlation between serum leptin levels and BMD [16], 
whereas other studies have noted no association between 
leptin and BMD [17]. Renal osteodystrophy (ROD) is a 
common complication of chronic renal failure (CRF). 
The Egyptian renal data system showed the prevalence 
of ROD to be 33.3% among dialysis patients [18]. 
Osteodystrophy is an important complication of chronic 
liver diseases (CLD) which includes both osteoporosis 
and osteomalacia. Both conditions are associated with 
significant morbidity through fractures, resulting in pain, 
deformity and immobility. This study was designed to 
evaluate serum leptin level in ESRD patients undergoing 
regular HD with or without liver disease. We aimed to 
evaluate the relationship between serum leptin level and 
bone mineral density in these groups of patients. The 
reduction in serum calcium among all patients groups as 
compared to the control group is similar to the results 
reported by Shenouda et al [19]. The hypocalcemia in 
CRF could be due to phosphorus retention, decreased 
calcitrol and skeletal resistance to the calcemic action of 
PTH. Elevated intact parathyroid hormone (PTH) among 
patients maintained on regular HD (group II and IV) 
may be explained by secondary hyperparathyroidism. 
It occurs early in the course of CRF mainly because of 
decreased calcitriol level, low serum calcium level and 
phosphorus retention [20].
Table 1:  Laboratory data of the studied groups
Group I Group II Group III Group IV P
Total calcium (mg/dl) 9.5 ± 0.6 7.3 ± 0.6 7.9 ± 0.7 7.4 ± 0.34 0.001
Corrected calcium (mg/dl) 9.38 ± 0.7 7.47 ± 0.8 8.85 ± 0.54 8.13 ± 0.56 0.001
Phosphorus (mg/dl) 4.1 ± 0.37 6.6 ± 1.36 4.455 ± 0.6 5.6 ± 1.5 0.001
PTH (pg/ml) 34.0 ± 12.3 124.7 ± 59 42.8 ± 19.4 111.7 ± 53.2 0.001
Serum leptin (ng/ml) 3.9 ± 0.98 15.07 ± 3.0 9.6 ± 3.9 12.4 ± 3.6 0.001
Urinary hydroxyproline (mg/24 hr) 13.2 ± 4.5 56.5 ± 17.6 40.5 ± 16.3 44.7 ± 16.6 0.001
Table 2:  Bone density measured by DEXA t-score (g/cm2) at lumbar spine and formal neck among studied groups
Group I Group II Group III Group IV P
Lumbar Spine  (g/cm2) -0.01 ± 0.65 -2.2 ± 0.85 -1.3 ± 0.44 -1.53 ± 0.55 0.001
Formal Neck  (g/cm2) -0.03 ± 0.52 -3.36 ± 0.58 -1.4 ± 0.47 -1.5 ± 0.5 0.001
Urinary hydroxyproline (mg/24 hr) 13.2 ± 4.5 56.5 ± 17.6 40.5 ± 16.3 44.7 ± 16.6 0.001
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the results obtained by Schiefke et al [22] as they have 
observed that urinary excretion of hydroxyproline was 
abnormally high in patients with liver cirrhosis. 
In the present study, there was a highly significant increase 
in serum leptin levels in all patient groups (II, III and IV) 
compared to control group. Elevated serum leptin level in 
CRF patients could be attributed to the reduced filtering 
ability of the kidney, causing leptin to accumulate in the 
serum [17, 23]. After renal transplantation the level of 
serum leptin falls. Elevated serum leptin level in CLD 
patients could be due to the inflammation induced by 
chronic viral hepatitis. Inflammatory mediators such as 
interlukin-1 (IL1) and tumour necrosis factor-α (TNF-α) 
stimulate leptin secretion [24]. Leptin may also have a 
role in the progression of hepatic fibrosis. Firstly, leptin 
increases the production of transforming growth factor-β 
(TGF-β), a potent profibrogenic cytokine which upregulates 
the production of extra cellular matrix from hepatic stellate 
cells (HSC) [25]. Secondly, elevated leptin levels may 
promote hepatic steatosis and steatohepatitis [26].
We found a highly significant decrease in BMD in all 
patient groups (II, III and IV) compared to controls. BMD 
was also significantly lower in HD patients without CLD 
(group II) compared to HD patients with CLD (group 
IV). The reduction in BMD among HD patients could 
be attributed to ROD, secondary hyperparathyroidism, 
adynamic bone disease or osteomalacia. Barnas et al [27] 
reported that skeletal changes are initiated at the early 
stages of CRF as estimated from reduced BMD due to 
high turnover bone loss.
Patients with ESRD and normal liver function (group 
II) displayed the typical profile of hypocalcemia, 
hyperphosphatemia, increased total ALP, high PTH, 
increased urinary hydroxyproline and decreased 
BMD. This is a cascade of metabolic and structural 
consequences following impairment of one-alpha 
hydroxylation and the influence of hyperphosphatemia 
which reflects the reduction in GFR. This leads to 
impaired calcium absorption, hypocalcemia, secondary 
hyperparathyroidism and increased bone turnover [28].
The reduction in BMD in CLD patients (groups III 
and IV) is most properly due to malnutrition, calcium 
malabsorption, immobilization and cholestasis. 
Hyperbilirubinemia inhibits osteoblast proliferation and 
decreases bone formation. Decreased BMD in CLD 
patients could also be due to hypogonadism, deficiency 
of vitamin D, treatment with glucocorticoids, and alcohol 
consumption [29].
In the present study, the prevalence of osteoporosis 
according to BMD measured by DEXA was significantly 
higher among HD patients without CLD (group II) 
Figure 1: Correlation between serum leptin (ng/ml) and the 
DEXA t-score of bone mineral density at the lumbar spine 
(g/cm2) in group II
Figure 2: Correlation between serum leptin (ng/ml) and the 
DEXA t-score of bone mineral density at the lumbar spine 
(g/cm2) in group III
Figure 3: Correlation between serum leptin (ng/ml) and the 
DEXA t-score of bone mineral density at the lumbar spine 
(g/cm2) in group IV
In this study, urinary hydroxyproline level was significantly 
higher in all patient groups (II, III and IV) compared to 
controls. Its level was significantly higher in HD patients 
without CLD (group II) compared to cirrhotic non uremic 
patients (group III). Elevated urinary hydroxyproline in 
ESRD patients indicates high bone turnover rate and 
high resorption of bone matrix, and concurs with the 
result obtained by Zoccali et al [21]. The increased level 
of urinary hydroxyproline in CLD patients was probably 
caused by active hepatic fibrogenesis and collagen 
remodelling in the diseased liver. This result agrees with 
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compared to ESRD patients with CLD (40% versus 10% 
at lumbar spine and 55% versus 5% at femoral neck). 
This suggests that cirrhosis modified the typical renal 
failure profile of ROD by decreasing high turnover bone 
loss and dialysis associated osteopenia and agrees with 
the result obtained by Shenouda et al [19].
In this study, there was no significant correlation between 
serum leptin level and BMD in ESRD patients. This 
contrasts with the findings obtained by Morberge et al 
[16], who reported that leptin inhibits bone formation. 
It also contrasts with the results reported by Ghazali et 
al [30] who found a positive correlation between serum 
leptin levels and BMD in HD patients, suggesting that 
leptin stimulates the bone formation.
We found a significant inverse relationship between 
serum leptin level and BMD in CLD patients This result 
is consistent with the results reported by Ormasdottir et al 
[31] who postulated that the central (inhibitory) effect of 
leptin predominates over its the peripheral (stimulatory) 
effect, contributing to the reduced bone formation in 
CLD patients. Steppan et al [14] demonstrated that 
peripheral administration of leptin to leptin-deficient ob/
ob mice stimulates bone growth and increases cortical 
bone formation considerably more than control groups. 
However, infusion of leptin into the cerebral ventricles 
caused bone loss in both leptin deficient and the wild type 
mice [32].
Caro et al [33] postulated that 25 ng/ml is the threshold 
above which leptin concentration in the cerebrospinal 
fluid (CSF) ceases to increase in correlation with serum 
level. Below that threshold, the centrally negative effects 
of leptin on BMD override the peripherally bone sparing 
effects [34]. Above that threshold there is no further 
increase in CSF leptin and no increase in its central 
inhibitory effects, but the positive peripheral effects 
of leptin continue to increase. That may explain the 
increased BMD among HD patients reported by Ghazali 
et al [30], as their patients serum leptin levels exceeded 
25 ng/dl. The positive correlation between serum leptin 
level and urinary hydroxyproline in all patient groups 
indicates a high rate of bone resorption. This agrees with 
the results obtained by Iwamoto et al [35] who found 
a positive correlation between serum leptin and bone 
resorption markers in pre-menopausal women.
Conclusion
From these observations, we can conclude that serum 
leptin level is elevated in ESRD patients treated with 
regular HD as well as CLD patients. The elevation of 
serum leptin is inversely correlated with BMD in CLD 
patients without liver disease, but not in other patient 
groups.
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